Depot risperidone-induced adverse metabolic alterations in
female rats

J 2017

Depot risperidone-induced adverse metabolic alterations in female rats

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ et. al.

Základní údaje

Originální název

Depot risperidone-induced adverse metabolic alterations in female rats

Autoři

HORSKÁ, Kateřina (203 Česká republika), Jana RUDÁ (203 Česká republika, garant, domácí), Michal KARPISEK (203 Česká republika), Radka OPATŘILOVÁ (203 Česká republika), Pavel SUCHÝ (203 Česká republika) a Hana KOTOLOVÁ (203 Česká republika)

Vydání

Journal of Psychopharmacology, London, SAGE Publications Ltd. 2017, 0269-8811

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.738

Kód RIV

RIV/00216224:14110/17:00096183

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1177/0269881117691466

UT WoS

000400179400009

Klíčová slova anglicky

Adipokine; depot risperidone; leptin; lipid profile; Sprague-Dawley rats

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 1. 2021 13:51, Ing. Marcela Sedlářová

Anotace

V originále

Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague–Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.

Návaznosti

ROZV/24/LF/2016, interní kód MU

Název: LF - Příspěvek IP 2016

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, LF - Příspěvek IP 2016

Citovat

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ a Hana KOTOLOVÁ. Depot risperidone-induced adverse metabolic alterations in female rats. Journal of Psychopharmacology. London: SAGE Publications Ltd., 2017, roč. 31, č. 4, s. 487-499. ISSN 0269-8811. Dostupné z: https://dx.doi.org/10.1177/0269881117691466.

@article{1373188,
   author = {Horská, Kateřina and Rudá, Jana and Karpisek, Michal and Opatřilová, Radka and Suchý, Pavel and Kotolová, Hana},
   article_location = {London},
   article_number = {4},
   doi = {http://dx.doi.org/10.1177/0269881117691466},
   keywords = {Adipokine; depot risperidone; leptin; lipid profile; Sprague-Dawley rats},
   language = {eng},
   issn = {0269-8811},
   journal = {Journal of Psychopharmacology},
   title = {Depot risperidone-induced adverse metabolic alterations in female rats},
   url = {http://journals.sagepub.com/doi/10.1177/0269881117691466},
   volume = {31},
   year = {2017}
}

TY  - JOUR
ID  - 1373188
AU  - Horská, Kateřina - Rudá, Jana - Karpisek, Michal - Opatřilová, Radka - Suchý, Pavel - Kotolová, Hana
PY  - 2017
TI  - Depot risperidone-induced adverse metabolic alterations in female rats
JF  - Journal of Psychopharmacology
VL  - 31
IS  - 4
SP  - 487-499
EP  - 487-499
PB  - SAGE Publications Ltd.
SN  - 02698811
KW  - Adipokine
KW  - depot risperidone
KW  - leptin
KW  - lipid profile
KW  - Sprague-Dawley rats
UR  - http://journals.sagepub.com/doi/10.1177/0269881117691466
L2  - http://journals.sagepub.com/doi/10.1177/0269881117691466
N2  - Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague–Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed. Concomitant to weight gain and increased liver weight, an adverse lipid profile with an elevated triglyceride level was observed in the high exposure group, administered a 40 mg/kg dose repeatedly, while the low dose exposure group, administered a 20 mg/kg dose, developed weight gain without alterations in the lipid profile and adipokine levels. An initial peak in leptin serum level after the higher dose was observed in the absence of weight gain. This finding may indicate that the metabolic alterations observed in this study are not consequent to body weight gain. Taken together, these data may support the primary effects of atypical antipsychotics on peripheral tissues.
ER  -

HORSKÁ, Kateřina, Jana RUDÁ, Michal KARPISEK, Radka OPATŘILOVÁ, Pavel SUCHÝ a Hana KOTOLOVÁ. Depot risperidone-induced adverse metabolic alterations in female rats. \textit{Journal of Psychopharmacology}. London: SAGE Publications Ltd., 2017, roč.~31, č.~4, s.~487-499. ISSN~0269-8811. Dostupné z: https://dx.doi.org/10.1177/0269881117691466.

Podrobný výpis o publikaci